CHEK1 and colorectal cancer: Given the reported ability of ATM loss to sensitise to ATR/CHK1 inhibition [38], and our recent finding that ATM loss synergises with IGF axis inhibition [14], we also tested ATM-deficient SK-CO-1 colorectal cancer (CRC) cells [39].